The company doesn't seem like it will generate pops in key fundamentals anytime soon.

The firm is projecting a gradual recovery of the academic market in the face of ongoing funding uncertainties and a government shutdown.

The outlook for full year 2025 remains unchanged at flat to 1% currency-neutral revenue growth, consistent with the Q2 update. Margins guidance is also unchanged. Q3 reported a slight revenue and ...

Bio-Rad Laboratories Inc. (BIO.B) on Wednesday reported a third-quarter loss of $341.9 million, after reporting a profit in the same period a ...

LOUISVILLE, Colo., Oct. 22, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (NYSE: BDSX), a leading diagnostics solutions company, today announced the signing of an expanded partnership agreement under which ...

Bio-Rad Laboratories Inc. reported its earnings for the second quarter of 2025, revealing a modest increase in net sales and a stable financial performance. Despite a challenging market environment, ...

One of the two candidates contesting the Irish presidential election has called on the Irish government to prepare for a united Ireland. Catherine Connolly, who has the support of a broad alliance of ...

Some soldiers announce support for protesters Protesters enter heavily-guarded city square for first time Protests pose a serious challenge to President Andry Rajoelina ANTANANARIVO, Oct 11 (Reuters) ...

PHILADELPHIA, Oct. 09, 2025 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell ...

NEW YORK – Bio-Rad Laboratories has obtained the CE mark for next-generation versions of its Specialty Immunoassay Plus quality control reagents, the firm said Wednesday. The SPIA Plus quality ...

-Clinical data to date supports a potentially transformational approach to treating autoimmune diseases with an off-the-shelf, one-time therapy- -As of the August 31, 2025 data cut-off date, all seven ...